Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Phase III RUBY clinical trial demonstrates potential of Jemperli ...
ESMO 2023 Insights: "Phase 3 RUBY Trial - Dostarlimab + Chemotherapy ...
Phase III RUBY Clinical Trial Shows Jemperli Could Redefine Cancer ...
Pressrelease: Phase III RUBY clinical trial demonstrates potential of ...
Behind the RUBY Trial of Dostarlimab and Chemo for Endometrial Cancer
Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial ...
RUBY trial results: The new standard of care in advanced/recurrent ...
Spectacular RUBY trial results with #Dostarlimab plus Chemotherapy ...
Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets ...
RUBY Part 2 trial results: Potentially practice changing results in ...
589 RUBY trial post hoc analysis of number needed to treat and ...
2023 ASCO® Direct Philadelphia: RUBY Trial Review - Dostarlimab + Chemo ...
ESMO: Update on the ENGOT-EN6 RUBY Trial | Oncology & Hematology FI
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial ...
An update on the Phase I/II RUBY trial of reni-cel gene therapy in ...
Real-World Data Support Dostarlimab Combo Benefit in RUBY Trial
Time to next treatment by age in the RUBY trial of dostarlimab in ...
RUBY Trial Dostarlimab Plus Carboplatin and Paclitaxel in Advanced ...
RUBY Trial Supports Addition of Dostarlimab to Chemo as SOC in ...
The Jack Ruby Trial - YouTube
RUBY Trial: Real-World Safety, Efficacy Analysis, and Quality of Life ...
Endometrial Cancer: Dostarlimab/Chemo Improves OS in Frontline RUBY ...
Managing Recurrent Endometrial Cancer: Treatment Strategies and RUBY ...
Red Ruby’: the trial flow chart. | Download Scientific Diagram
Phase 3 RUBY Trial: Dostarlimab Combination Prolongs Time to Next ...
RUBY Trial: Dostarlimab Boosts Survival in Endometrial Cancer With ...
ASCO® 2023 Insights: "RUBY Trial Summary on Dostarlimab + Chemo for ...
RUBY's Phase III clinical trial using Jemperli (dostarlimab) and ...
ENGOT-EN6-NSGO/GOG-3031/RUBY trial results: The new standard of care in ...
Inside the Jack Ruby Trial: Historic 1964 Footage from Dallas ...
ENGOT-EN6/GOG-3031/NSGO-RUBY STUDY – Nordic Society of Gynaecological ...
Omnihealth Practice | Dostarlimab + carboplatin/paclitaxel shows ...
Overall survival in patients with endometrial cancer treated with ...
First-line immunotherapy prolongs survival in endometrial cancer
Updates in the Treatment of Advanced/Recurrent Endometrial Cancer: Data ...
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer ...
Overall Survival in Patients with Endometrial Cancer Treated with ...
Omnihealth Practice | Long-term HRQoL outcomes of dostarlimab ...
Selected ESMO 2023 Highlights: Endometrial Cancer Treatment
Clinical Trials - Okogen
Overall survival among patients with primary advanced or recurrent ...
Overall Survival in Patients With Primary Advanced or Recurrent ...
GSK’s oncology drug, Jemperli, meets its co-primary endpoint of overall ...
Endometrial Cancer
OVERALL SURVIVAL IN PATIENTS WITH ENDOMETRIAL CANCER TREATED WITH ...
Evolving Treatment Landscape in Endometrial Cancer | Published in ...
Dostarlimab in Combination with Chemotherapy for the Treatment of ...
SURVIVAL AND SAFETY OUTCOMES IN PART 1 OF THE ENGOT-EN6-NSGO/GOG-3031 ...
Patient-Reported Outcomes In Patients With Primary Advanced Or ...
639 Management of immune-related adverse events in patients with ...
Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib ...
PO001/#1130 Impact of investigator-assessed response to dostarlimab on ...
PO002/#638 Efficacy and safety of dostarlimab plus chemotherapy in ...
37MO Dostarlimab plus chemotherapy in primary advanced or recurrent ...
Dostarlimab Earns Priority Review From FDA In Advanced Endometrial Cancer
Time Course Of Adverse Events In Primary Advanced Or Recurrent ...
